SUPAC modified-release draft guidance allows annual report for batch variations under 2%.

DRAFT SUPAC GUIDANCE COVERING MODIFIED-RELEASE DRUGS ALLOWS ANNUAL REPORT filing for changes that represent less than a 2% bath variation in release-controlling excipients. The Scale-Up and Postapproval Changes draft for Modified Release Solid Oral Dosage Forms states that for Level 1 changes, a "total additive effect of all release controlling excipient changes should not be more than 2% [by weight] of the total release controlling excipients in the original approved formulation."

More from Archive

More from Pink Sheet

Advocates Want New Bipartisan PBM Reform Package To Stand Alone

 
• By 

A new PBM reform package has familiar provisions, but stakeholders want it to move as a stand-alone bill, rather than as part of a larger legislative vehicle.

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda

 
• By 

The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.

Gene Therapy Elevidys Among Six Orphan Drugs Awaiting EU Marketing Verdict

 
• By 

The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.